J&J says MajesTEC-3 analysis projects near-general-population mortality risk for Tecvayli-Darzalex combo in early relapsed myeloma

• Johnson & Johnson released new model-based analyses from the Phase 3 MajesTEC-3 trial in relapsed or refractory multiple myeloma.
• Results will be presented in two oral sessions at the International Myeloma Society Annual Meeting.
• Modeling suggests the Tecvayli-Darzalex Faspro regimen could deliver durable disease control, reshaping long-term survival expectations at first relapse.
• A separate analysis attributed the survival advantage mainly to fewer relapses versus standard regimens, without a meaningful rise in other deaths.
• The readout supports the company’s push to move its BCMA bispecific therapy into earlier lines, reinforcing a potential new standard of care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609230946PR_NEWS_USPR_____NY54428) on September 23, 2026, and is solely responsible for the information contained therein.